Esobiz-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastroesophageal reflux disease (GERD), dyspepsia, and related gastrointestinal disorders. Esomeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby promoting mucosal healing and symptom relief. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility and accelerates gastric emptying, reducing symptoms such as nausea, vomiting, and bloating commonly associated with delayed gastric emptying and reflux. The synergistic action of these two agents provides comprehensive symptomatic relief by addressing both acid hypersecretion and impaired motility. Esobiz-DSR is indicated for patients with erosive esophagitis, non-erosive reflux disease (NERD), and functional dyspepsia where acid suppression alone is insufficient. It should be administered as prescribed by a healthcare professional, typically before meals, to optimize therapeutic outcomes. Caution is advised in patients with cardiac arrhythmias or electrolyte imbalances due to the potential proarrhythmic effects of Domperidone. Regular monitoring and adherence to prescribed dosage are essential to minimize adverse effects and ensure efficacy.